Management of acute exacerbations in multiple sclerosis

Annals of Indian Academy of Neurology

Volumn 12, Issue 4, 2009, Pages 264-272

  Ontaneda, Daniel ^a   Rae Grant, Alex D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Exacerbation; Management; Multiple sclerosis; Relapse; Steroids

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN; METHYLPREDNISOLONE; NATALIZUMAB; PLACEBO;

ASEPTIC MENINGITIS; ASEPTIC NECROSIS; BEDTIME DOSAGE; BIOLOGICAL ACTIVITY; BRAIN ATROPHY; CATARACT; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; COST OF ILLNESS; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPEPSIA; EUPHORIA; FLUSHING; GASTROINTESTINAL SYMPTOM; GLUCOSURIA; HEART ARRHYTHMIA; HEART INFARCTION; HEMOLYSIS; HUMAN; HYPERGLYCEMIA; IMAGING; INSOMNIA; KIDNEY DISEASE; LOW DRUG DOSE; MEMORY; META ANALYSIS; MORNING DOSAGE; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PARESTHESIA; PATHOPHYSIOLOGY; PHARYNGITIS; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; SIDE EFFECT; SYMPTOM; SYSTEMATIC REVIEW; TASTE DISORDER; THROMBOSIS; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 72949119691     PISSN: 09722327     EISSN: 19983549     Source Type: Journal    
DOI: 10.4103/0972-2327.58283     Document Type: Review

References (89)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;37264: 1502-1517
2. Lublin FD. The incomplete nature of multiple sclerosis relapse resolution. J Neurol Sci 2007;256:S14-8.
3. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: A geographically based study: 2: Predictive value of the early clinical course. Brain 1989 ;112:1419-1428 (Pubitemid 20024212)
4. Schumacker GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, McDowell F, et al. Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965;122:552-568
5. Wingerchuk DM, Rodriguez M. Premenstrual multiple sclerosis pseudoexacerbations: Role of body temperature and prevention with aspirin. Arch Neurol 2006;63:1005-1008
6. Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002;125:952-960
7. Smith ME, Stone LA, Albert PS, Frank JA, Martin R, Armstrong M, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumineenhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480-489
8. Frohman EM, Racke MK, Raine CS. Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med 2006;354:942-955
9. Fischer FR, Santambrogio L, Luo Y, Berman MA, Hancock WW, Dorf ME. Modulation of experimental autoimmune encephalomyelitis: Effect of altered peptide ligand on chemokine and chemokine receptor expression. J Neuroimmunol 2000;110:195-208.
10. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000;192:393-404.
11. Ando DG, Clayton J, Kono D, Urban JL, Sercarz EE. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the th-1 lymphokine subtype. Cell Immunol 1989;124:132-143
12. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002;8:500-508
13. Gran B, Zhang GX, Rostami A. Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inßammatory demyelination. Crit Rev Immunol 2004;24:111-128
14. Li H, Cuzner ML, Newcombe J. Microglia-derived macrophages in early multiple sclerosis plaques. Neuropathol Appl Neurobiol 1996;22:207-215
15. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285
16. Smith KJ, McDonald WI. The pathophysiology of multiple sclerosis: The mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 1999;35439:1649-1673
17. Waxman SG. Conduction in myelinated, unmyelinated and demyelinated fibers. Arch Neurol 1977;34:585-589
18. Waxman SG. Sodium channel blockade by antibodies: A new mechanism of neurological disease? Ann Neurol 1995;37:421-423
19. Calabrese V, Scapagnini G, Ravagna A, Bella R, Foresti R, Bates TE, et al. Nitric oxide synthase is present in the cerebrospinal ßuid of patients with active multiple sclerosis and is associated with increases in cerebrospinal ßuid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels. J Neurosci Res 2002;70:580-587
20. Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996;119:225-237
21. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58:445-452
22. Nesbit GM, Forbes GS, Scheithauer BW, Okazaki H, Rodriguez M. Multiple sclerosis: Histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 1991;180:467-474
23. Masdeu JC, Quinto C, Olivera C, Tenner M, Leslie D, Visintainer P. Open-ring imaging sign: Highly Specific for atypical brain demyelination. Neurology 2000;54:1427-1433
24. Kermode AG, Tofts PS, Thompson AJ, MacManus DG, Rudge P, Kendall BE, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: An MRI study with gadolinium-DTPA enhancement. Neurology 1990;40:229-235
25. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history. Ann Neurol 1991;29:548-555
26. Willoughby EW, Grochowski E, Li DK, Oger J, Kastrukoff LF, Paty DW. Serial magnetic resonance scanning in multiple sclerosis: A second prospective study in relapsing patients. Ann Neurol 1989;25:43-49
27. Patzold U, Pocklington PR. Course of multiple sclerosis: First results of a prospective study carried out of 102 MS patients from 1976-1980. Acta Neurol Scand 1982;65:248-266
28. Confavreux C, Vukusic S. Natural history of multiple sclerosis: A unifying concept. Brain 2006;129:606-616 (Pubitemid 43278223)
29. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528-1532
30. Buljevac D, Hop WC, Reedeker W, Janssens AC, Van der Meche FG, Van Doorn PA, et al. Self reported stressful life events and exacerbations in multiple sclerosis: Prospective study. BMJ 2003;32741:646.
31. Persoons JH, Schornagel K, Breve J, Berkenbosch F, Kraal G. Acute stress affects cytokines and nitric oxide production by alveolar macrophages differently. Am J Respir Crit Care Med 1995;152:619-624
32. O'Brien JA, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the united states. BMC Health Serv Res 2003;3:17.
33. Devins GM, Edworthy SM, Seland TP, Klein GM, Paul LC, Mandin H. Differences in illness intrusiveness across rheumatoid arthritis, end-stage renal disease, and multiple sclerosis. J Nerv Ment Dis 1993;181:377-381
34. Dalos NP, Rabins PV, Brooks BR, O'Donnell P. Disease activity and emotional state in multiple sclerosis. Ann Neurol 1983;13:573-577
35. Frohman EM, Shah A, Eggenberger E, Metz L, Zivadinov R, Stuve O. Corticosteroids for multiple sclerosis: I: Application for treating exacerbations. Neurotherapeutics 2007;4:618-626 (Pubitemid 47499290)
36. Edlund W, Gronseth G, So Y, Franklin G. AAN clinical practice guideline process manual. St Paul: American Academy of Neurology; 2005.
37. Frohman EM, Shah A, Eggenberger E, Metz L, Zivadinov R, Stüve O. Corticosteroids for multiple sclerosis: I. application for treating exacerbations. Neurotherapeutics 2007;4:618-626 (Pubitemid 47499290)
38. Wehling. Specific, nongenomic actions of steroid hormones. Annu Rev Physiol 1997;59:365-393
39. Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 2006;63:60-72.
40. Orchinik M, Murray TF, Moore FL. A corticosteroid receptor in neuronal membranes. Science 1991;25201:1848-1851
41. Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: Possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 2001;117:1-8.
42. McCombe PA, Nickson I, Tabi Z, Pender MP. Corticosteroid treatment of experimental autoimmune encephalomyelitis in the lewis rat results in loss of V beta 8.2+ and myelin basic protein-reactive cells from the spinal cord, with increased total T-cell apoptosis but reduced apoptosis of V beta 8.2+ cells. J Neuroimmunol 1996;70:93-101.
43. Schmidt J, Gold R, Schonrock L, Zettl UK, Hartung HP, Toyka KV. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 2000;123:1431-1441
44. Elovaara I, Lalla M, Spare E, Lehtimaki T, Dastidar P. Methylprednisolone reduces adhesion molecules in blood and cerebrospinal ßuid in patients with MS. Neurology 1998;51:1703-1708
45. Gelati M, Corsini E, De Rossi M, Masini L, Bernardi G, Massa G, et al. Methylprednisolone acts on peripheral blood mononuclear cells and endothelium in inhibiting migration phenomena in patients with multiple sclerosis. Arch Neurol 2002;59:774-780
46. Rosenberg GA, Dencoff JE, Correa N Jr, Reiners M, Ford CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: Relation to blood-brain barrier injury. Neurology 1996;46:1626-1632
47. Sellebjerg F, Christiansen M, Jensen J, Frederiksen JL. Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. Eur J Neurol 2000;7:281-289
48. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: Report of the therapeutics and technology assessment subcommittee of the American academy of neurology and the MS council for clinical practice guidelines. Neurology 2002;58:169-178
49. Beck RW. The optic neuritis treatment trial. Arch Ophthalmol 1988;106:1051-1053
50. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Doubleblind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998;51:529-534
51. Durelli L, Cocito D, Riccio A, Barile C, Bergamasco B, Baggio GF, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: Clinical-immunologic correlations. Neurology 1986;36:238-243
52. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1: Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-516
53. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: A meta-analysis of randomized controlled clinical trials. J Neurol 2000;247:435-442
54. Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, Midgard R, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000;CD001331.
55. Barnes D, Hughes RA, Morris RW, Wade-Jones O, Brown P, Britton T, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997;34905:902-906 (Pubitemid 27139818)
56. Alam SM, Kyriakides T, Lawden M, Newman PK. Methylprednisolone in multiple sclerosis: A comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993;56:1219-1220
57. La Mantia L, Eoli M, Milanese C, Salmaggi A, Dufour A, Torri V. Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. Eur Neurol 1994;34:199-203.
58. Oliveri RL, Valentino P, Russo C, Sibilia G, Aguglia U, Bono F, et al. Randomized trial comparing two different high doses of methylprednisolone in MS: A clinical and MRI study. Neurology 1998;50:1833-1836
59. Glass-Marmor L, Paperna T, Ben-Yosef Y, Miller A. Chronotherapy using corticosteroids for multiple sclerosis relapses. J Neurol Neurosurg Psychiatry 2007;78:886-888
60. Barkhof F, Frequin ST, Hommes OR, Lamers K, Scheltens P, Van Geel WJ, et al. A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurology 1992;42:63-67
61. Frequin ST, Barkhof F, Lamers KJ, Hommes OR. The effects of high-dose methylprednisolone on gadolinium-enhanced magnetic resonance imaging and cerebrospinal ßuid measurements in multiple sclerosis. J Neuroimmunol 1992;40:265-272
62. Oliveri RL, Valentino P, Russo C, Sibilia G, Aguglia U, Bono F, et al. Randomized trial comparing two different high doses of methylprednisolone in MS: A clinical and MRI study. Neurology 1998;50:1833-1836
63. Barkhof F, Tas MW, Frequin ST, Scheltens P, Hommes OR, Nauta JJ, et al. Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. Neuroradiology 1994;36:382-387
64. Perumal JS, Caon C, Hreha S, Zabad R, Tselis A, Lisak R, et al. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis. Eur J Neurol 2008;15:677-680
65. Zawadzka M, Franklin RJ. Myelin regeneration in demyelinating disorders: New developments in biology and clinical pathology. Curr Opin Neurol 2007;20:294-298
66. Chari DM, Zhao C, Kotter MR, Blakemore WF, Franklin RJ. Corticosteroids delay remyelination of experimental demyelination in the rodent central nervous system. J Neurosci Res 2006;83:594-605.
67. Chapman C, Tubridy N, Cook MJ, Mitchell PJ, MacGregor LR, Lovelock C, et al. Short-term effects of methylprednisolone on cerebral volume in multiple sclerosis relapses. J Clin Neurosci 2006;13:636-638
68. Fox RJ, Fisher E, Tkach J, Lee JC, Cohen JA, Rudick RA. Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: Short-term changes and long-term implications. Mult Scler 2005;11:140-145
69. Oliveri RL, Sibilia G, Valentino P, Russo C, Romeo N, Quattrone A. Pulsed methylprednisolone induces a reversible impairment of memory in patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand 1998;97:366-369
70. Uttner I, Muller S, Zinser C, Maier M, Sussmuth S, Claus A, et al. Reversible impaired memory induced by pulsed methylprednisolone in patients with MS. Neurology 2005 14;64:1971-1973
71. Dovio A, Perazzolo L, Osella G, Ventura M, Termine A, Milano E, et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 2004;89:4923-4928
72. Zorzon M, Zivadinov R, Locatelli L, Giuntini D, Toncic M, Bosco A, et al. Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 2005;12:550-556
73. Lyons PR, Newman PK, Saunders M. Methylprednisolone therapy in multiple sclerosis: A profile of adverse effects. J Neurol Neurosurg Psychiatry 1988;51:285-287
74. Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F. B cells and multiple sclerosis. Lancet Neurol 2008;7:852-858
75. Elovaara I, Apostolski S, Van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008;15:893-908.
76. Schilling S, Linker RA, Konig FB, Koziolek M, Bahr M, Muller GA, et al. Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: Clinical experience with 16 patients. Nervenarzt 2006;77:430-438
77. Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, et al. A randomized trial of plasma exchange in acute central nervous system inßammatory demyelinating disease. Ann Neurol 1999;46:878-886
78. Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R. Plasma exchange for severe optic neuritis: Treatment of 10 patients. Neurology 2004;63:1081-1083
79. Linker RA, Chan A, Sommer M, Koziolek M, Muller GA, Paulus W, et al. Plasma exchange therapy for steroid-refractory superimposed relapses in secondary progressive multiple sclerosis. J Neurol 2007;254:1288-1289
80. Soukop W, Tschabitscher H. Gamma globulin therapy in multiple sclerosis. theoretical considerations and initial clinical experiences with 7S immunoglobulins in MS therapy. Wien Med Wochenschr 1986;136:477-480
81. Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M; TARIMS Study Group. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 2004;63:2028-2033
82. Rigas M, Tandan R, Sterling RJ. Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: A retrospective analysis of 1085 infusions. J Clin Neuromuscul Dis 2008;10:52-55
83. Rodnitzky RL, Goeken JA. Complications of plasma exchange in neurological patients. Arch Neurol 1982;39:350-354
84. Henze T, Prange HW, Talartschik J, Rumpf KW. Complications of plasma exchange in patients with neurological diseases. Klin Wochenschr 1990;68:1183-1188
85. Couriel D, Weinstein R. Complications of therapeutic plasma exchange: A recent assessment. J Clin Apher 1994;9:1-5.
86. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007;356:2622-2629
87. O'Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, et al. Randomized multicenter trial of natalizumab in acute MS relapses: Clinical and MRI effects. Neurology 2004;62:2038-2043
88. Craig J, Young CA, Ennis M, Baker G, Boggild M. A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment. J Neurol Neurosurg Psychiatry 2003;74:1225-1230
89. Bethoux F, Miller DM, Kinkel RP. Recovery following acute exacerbations of multiple sclerosis: From impairment to quality of life. Mult Scler 2001;7:137-142